- Home
- ESQ vs KURA Comparison
ESQ vs KURA Comparison
Compare ESQ & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESQ | KURA |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 841.6M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ESQ | KURA |
|---|---|---|
| Price | $109.72 | $10.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $120.33 | $25.56 |
| AVG Volume (30 Days) | 77.0K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $35.15 | $28.28 |
| Revenue Next Year | $39.09 | $106.37 |
| P/E Ratio | $78.29 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $87.54 | $5.45 |
| 52 Week High | $119.86 | $12.49 |
Technical Indicators
Market Signals| Indicator | ESQ | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 56.79 |
| Support Level | $103.31 | $8.80 |
| Resistance Level | $111.41 | $11.17 |
| Average True Range (ATR) | 2.81 | 0.63 |
| MACD | 0.36 | 0.04 |
| Stochastic Oscillator | 58.02 | 53.80 |
Price Performance
Historical ComparisonAbout ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.